Lorcaserin 10 mg vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0365 | 0.0321 | 0.0416 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0337 | 0.0294 | 0.0386 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00282 | -0.00379 | 0.00944 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.08 | 0.898 | 1.31 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.09 | 0.895 | 1.32 | log | ClinicalTrials.gov | |
| Number needed to harm, for one more death from any cause on Lorcaserin 10 mg than on Placebo | 355 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Lorcaserin 10 mg | Participants received lorcaserin HCL 10 milligram (mg), tablets, orally, twice daily for up to 52 months. | 219 | 5,995 | EG001 | ClinicalTrials.gov |
| Group 2 | Placebo | Participants received lorcaserin HCL placebo-matching, tablets, orally, twice daily for up to 52 months. | 202 | 5,992 | EG000 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | From baseline up to 30 days after last dose of study drug (approximately 56 months) | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | ClinicalTrials.gov |
| NCT number | NCT02019264 | ClinicalTrials.gov |
| Phases | PHASE4 | ClinicalTrials.gov |
| Conditions | Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes | ClinicalTrials.gov |
| Interventions | Lorcaserin hydrochloride, Placebo | ClinicalTrials.gov |
| Lead sponsor | Eisai Inc. | ClinicalTrials.gov |
| Results first posted | 2019-07-16 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02019264?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.